Affymetrix Breaks 100K Barrier

Courtesy of AffymetrixMicroarray giant Affymetrix http://www.affymetrix.com of Santa Clara, Calif., is raising the bar for whole-genome association studies. The first in a planned line of related products, the two-array GeneChip® Mapping 100K set can genotype over 100,000 single nucleotide polymorphisms (SNPs), 10 times more than its predecessor could.About half of the SNPs on the 100K set come from public databases. The rest stem from a proprietary database developed by Perlegen Sciences o

Written byStephen Pincock
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Courtesy of Affymetrix

Microarray giant Affymetrix http://www.affymetrix.com of Santa Clara, Calif., is raising the bar for whole-genome association studies. The first in a planned line of related products, the two-array GeneChip® Mapping 100K set can genotype over 100,000 single nucleotide polymorphisms (SNPs), 10 times more than its predecessor could.

About half of the SNPs on the 100K set come from public databases. The rest stem from a proprietary database developed by Perlegen Sciences of Mountain View, Calif. More SNPs from both public sources and the Perlegen database will be added to next-generation arrays, Affymetrix says.

The 100K set follows from Affymetrix's earlier GeneChip Mapping 10K array. Dietrich Stephan, from the Translational Genomics Research Institute in Phoenix, Ariz., says his group has used this earlier array to examine about 20 pedigrees so far. "The throughput and accuracy for doing whole-genome linkage analysis is unprecedented. It's at least an order of magnitude ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies